{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.0","value":"3510"}]}],"title":"Abemaciclib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.0","value":"1620"}]}],"title":"M2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.0","value":"2750"}]}],"title":"M20"}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC\\[0-∞\\]) was evaluated for Abemaciclib and Metabolites M2 and M20","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Abemaciclib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants who received at least one dose of study drug (Abemaciclib) with evaluable Abemaciclib, M2 and M20 pharmacokinetic (PK) data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 pre dose, Cycle 1 Day 15 4 hours (h) and 7 h post dose, Cycle 2 Day 1 pre dose and 3 h post dose, Cycle 3 Day1 pre dose","title":"Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) for Abemaciclib and Metabolites M2 and M20","type":"SECONDARY","unitOfMeasure":"Nanograms*hour/milliliters (ng*h/mL)]"}